ADVI Health

ADVI Health's claims data represents nearly 6.6 million #Medicare FFS beneficiaries who have a #diabetes diagnosis of both type 1 and type 2. This demographic represents approximately 13.8 percent of the entire Medicare FFS beneficiary population. Our team found that their annual Medicare expenditures are 105 percent higher than the average Medicare FFS beneficiary and make up 28 percent of total Medicare spend. Learn more about our Strategic Analytics, Value and Economics (SAVEs) team's datasets and how we couple them with our expertise to provide insights: https://lnkd.in/epX6qd5R #NationalDiabetesMonth #DiabetesAwarenessMonth

📅 Next week, ADVI Health senior advisor, Norris Turner, PharmD, PhD, will be attending the AMCP Foundation Research Symposium on December 3-4 in Dallas, TX. While there, Norris will moderate the panel discussion, "Addressing Disparities in the Evidence-Based Use of Biomarker-Driven Precision Oncology," which will expand on how access to and receipt of appropriate biomarker testing must be an attainable goal to ensure equal access to quality care. Joining him will be esteemed panelists Ira Klein, MD, MBA and Lalan Wilfong, M.D. for what promises to be a powerful conversation shaping the future of precision #oncology. Get in touch and learn more: https://lnkd.in/gJzZvvVy

#ICYMI: ADVI Health's CEO, Marc Samuels, spoke at and moderated an executive leadership roundtable for the Association for Value-Based Cancer Care Annual Summit on October 16 in New York. The panel included several notable executives from biopharma companies representing market access, communications, brand, and R&D functions. Their conversation included several insights on topics like the uncertainty and volatility in the sector given the policy positions of both presidential candidates, innovators in trial design and development through artificial intelligence, the level of activity at the state level, and the ongoing evolution in the cancer care landscape. Hear Marc's key takeaways: https://lnkd.in/eUCbQ74x

Lindsay Bealor Greenleaf, head of federal and state policy at ADVI Health, recently shared her perspective on pharmacy benefit managers (PBMs) in Modern Healthcare's article, "PBM bill, telehealth extension may ride together in 'lame duck,'" including how observers should keep their eyes on some of the measures that increase transparency or untether PBMs’ compensation from a drug’s price. Read more of Lindsay's insights: https://lnkd.in/g8KBzaDx

ADVI Health's team of leading #marketaccess and #biopharma experts understand and translate the impact of policy implementations for our clients and their product lifecycle. We form comprehensive and informed solutions based on our client's needs to ensure strategic guidance while working closely with #pharmaceutical and device manufacturers, and our collaborative and partner-based approach across all ADVI solutions is what allows us to ensure client success. Learn more about our market access and biopharma expertise: https://lnkd.in/eCh3_sQx #ADVISolutionSpotlight

ADVI Health recently conducted a survey of patients' experiences and specialty medication access with alternative funding programs (AFPs), which was published in the Journal of Managed Care & Specialty Pharmacy (JMCP). The survey consisted of 26 single- and multiple-choice questions to assess patients’ awareness of AFPs from their employers, experience with the patient assistance program application process via the AFP vendor, timeliness of medication access, and the health impact of delays. Responses were analyzed by disease and income level. A greater proportion of patients with hemophilia reported being anxious from waiting for their medication. Patients with lower income levels reported longer wait times. Read the full results of the study: https://lnkd.in/g3EyNaKt

Get to know Cynthia Campos, a senior researcher at ADVI Health. Bringing several years of expertise working on health outcomes studies for pharmaceutical and life sciences companies to the team, Cynthia works on a variety of projects at ADVI, including claims algorithms, systematic literature reviews, medical chart reviews, and expert Delphi panels. Learn more about Cynthia: https://lnkd.in/g4Dd-pY7 #ADVIExpertSpotlight

ADVI Health's head of federal and state policy, Lindsay Bealor Greenleaf, recently sat down with MedCity News to share insight on how a Trump administration will likely shake up the prescription drug world. In the article, "What Might the Future of Prescription Drugs Look Like Under Trump?," Lindsay discusses how she anticipates these changes will affect the #InflationReductionAct (IRA). Read the full article: https://lnkd.in/gUwCqgAn

Recently conducting a study on examining access to specialty medications through alternative funding programs (AFPs), ADVI Health Strategic Analytics, Value and Economics (SAVEs) senior director, Irina Yermilov, MD, MPH, MS, dives into these insights derived by her and her team - which was among one of the top four abstracts at this year's AMCP Nexus and received the Platinum Award. The study found that 61 percent of patients learned about AFPs as part of their health plan benefits while trying to obtain specialty medications rather than directly from their employer. 54 percent reported feeling uncomfortable with the AFP vendor representative, often feeling hesitant to share sensitive information. Learn more about this study: https://lnkd.in/e9ACBk2H

Last week, ADVI Health's head of federal and state policy, Lindsay Bealor Greenleaf, was featured in AJMC - The American Journal of Managed Care's article, "The Trump Sequel: What to Expect on PBMs, 340B, Drug Pricing, and RFK Jr." Lindsay shared her post-election insights on where she thinks these policies will stand during the lame duck period, and what she is watching for ahead of Trump's second administration. Read more of Lindsay's insights: https://lnkd.in/gDDuAzY8